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Abstract
Background: Methotrexate (MTX) is an antimetabolite broadly used in treatment of cancer and autoimmune
diseases. MTX-induced hepatotoxicity limits its application. We investigated hepatoprotective effects of turmeric in
MTX-induced liver toxicity.
Methods: All experiments were performed on male Wistar albino rats that were randomly divided into six
groups. Group one received saline orally for 30 days (control group), groups two and three received turmeric
extract (100, 200 mg/kg respectively) orally for 30 days, group four received single dose, of MTX IP at day 30,
groups five and six received turmeric extract 100 and 200 mg/kg orally respectively for 30 days and single dose
of methoterxate IP (20 mg/kg) at day 30. Four days after MTX injection animals were sacrificed and evaluated.
Blood ALT and AST (indicators of hepatocyte injury), ALP and bilirubin (markers of biliary function), albumin
(reflect liver synthetic function) as well as the plasma TAS concentration (antioxidant defenses) were determined.
The cellular antioxidant defense activities were examined in liver tissue samples using SOD, CAT, and GSH-Px for
the oxidative stress, and MDA for lipid peroxidation. In addition, liver damage was evaluated histopathologically.
Results: MTX significantly induced liver damage (P < 0.05) and decreased its antioxidant capacity, while turmeric
was hepatoprotective. Liver tissue microscopic evaluation showed that MTX treatment induced severe centrilobular
and periportal degeneration, hyperemia of portal vein, increased artery inflammatory cells infiltration and necrosis,
while all of histopathological changes were attenuated by turmeric (200 mg/kg).
Conclusion: Turmeric extract can successfully attenuate MTX-hepatotoxicity. The effect is partly mediated
through extract’s antinflammatory activity.
Keywords: Lipid peroxides, Total antioxidant status, Antioxidant enzymes, Serum liver biomarkers, Hepatocellular
injury, Cell death
Background
MTX has is a versatile drug that has been clinically
applied in a wide range of diseases including systemic
lupus erythematosus, rheumatoid arthritis, psoriasis, and
neoplastic diseases [1–4]. The therapeutic applications
of MTX is usually limited by its severe hepatotoxicity
which causes malabsorption and diarrhea in the patients
[5, 6]. The underlying mechanism of MTX-induced hep-
atotoxicity has not been fully identified, however, several
distinct mechanisms have been proposed including cel-
lular antioxidant defense deregulation which cause more
oxidative stress-induced damages to the liver cells [7].
Mitochondria are the primary intracellular target for oxi-
dative stress [8], however reactive oxygen metabolites
scavenger systems like superoxide dismutase (SOD),
glutathione peroxidase (GPx), catalase and glutathione-
S-transferrase (GST), continuously remove ROS and
maintain mitochondria function in an steady state
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[9, 10]. MTX is indirectly involved in liver mitochondria
damage via depletion of mitochondria enzymatic and
non-enzymatic antioxidants machinery [11–13]. MTX
administration may also cause the accumulation of re-
active oxygen species (ROS), targeting macromolecules
and many pathological processes [14, 15]. The first line
of defense against the cell damaging effects of oxidative
stress for liver is antioxidant defense system which
neutralizes the deleterious effects of free radicals [16].
Therefore, the level of ROS in liver tissue may be esti-
mated by the analysis of the antioxidant enzymes activity
including superoxide dismutase (SOD), catalase (CAT),
and glutathione-S-transferase (GST) [17, 18].
Turmeric (Curcuma longa L., zingiberaceae), is a
yellow-colored spice derived from the perennial herb,
which has been widely used for centuries in traditional
therapies for different diseases including cancer, inflam-
matory disorders, hepatitis and other liver disorders,
skin diseases, Alzheimer’s disease, rheumatoid arthitis
[19–22]. Besides curcumin, turmeric contains more than
300 other components, including, notably phenolics and
terpenoids which may more widely and strongly affect
various molecular and biochemical cascades [23, 24].
Turmeric provides protection against hepatic damage
induced by free radicals and attenuates hepatic lipid
peroxidation [25, 26]. Previously, it has been shown in a
short term-trial (five days), that curcumin, a main inte-
grant of turmeric, could alleviate hepatic injury induced
by MTX, when applied after MTX treatment [13]. How-
ever, Gupta and colleagues concluded that the effect of
whole turmeric may markedly differ from curcumin
itself [27]. The effect of long term administration of
whole turmeric on hepatic injury induced by MTX are
yet completely unknown. In the current study, using a
rat model, we have investigated the effect of pre-
administration of turmeric in MTX-induced liver injury.
The observed effects were assessed by measuring the
levels of antioxidant enzymes, lipid peroxidation marker,
total antioxidant status, as well as biochemical and his-
topathologic evaluations.
Methods
Animals and study protocol
Experiments were performed on male Wistar Albino rats
weighing between 220–280 g purchased from Drug
Applied Research Center, Tabriz University of Medicine
Science. Rats were kept in 12 h light and 12 h dark cycle
at the temperature of 21 ± 2 °C, food and water were
available ad libitum throughout the study. Investigations
using experimental animals were conducted in accordance
with the internationally accepted principles for laboratory
animal use and care as found in the United States guide-
lines (United States National Institutes for Health publica-
tion # 85–23, revised in 1985) and the Institutional
Animal Ethics Committee of the Ardabil University of
Medical Sciences approved the protocol (# 90374).
42 rats were randomly divided into six groups, group I
received normal saline orally for 30 days (control group),
group II and III received oral turmeric extract (100 and
200 mg/kg respectively) by gastric gavages for 30 days,
group IV received single IP MTX (20 mg/kg) on day 30,
group V received oral turmeric extract (100 mg/kg) for
30 days and IP single dose of MTX (20 mg/kg) on day 30,
and group VI received oral turmeric extract (200 mg/kg)
for 30 days and IP single dose of MTX (20 mg/kg) on day
30. Four days after MTX injection animals were anesthe-
tized; blood and tissue samples were collected for different
experiments. Study protocol is summarized in Table 1.
Chemicals
MTX was purchased from EBEWE Pharma Ges, Austria.
All kits were provided by Randox® (Cat No. NX2332,
Randox laboratories, Ltd, Crumlin, UK). Dimethyl sulf-
oxide (DMSO), ethylene diamine tetracetic acid (EDTA)
3-(4,5-dimethylthiazol-2-yl), ethanol, ethyl acetate, Tris
HCl, 2-thiobarbituric acid (TBA) and other chemicals
were obtained from Sigma Chemical Co. (St Louis, MO,
USA). All chemicals used were analytical grade. Tur-
meric (Curcuma longa L., Zingiberaceae) was purchased
from the local market and identified by the Department
of Cultivation and Development of Institute of Medical
Plants, Tehran, Iran. The plant was then thoroughly
washed, air dried, and grinded to a uniform powder.
Turmeric powder (10 g) was mixed in distilled ethanol
(100 ml) for 3 h at room temperature and was then cen-
trifuged at 2500 rpm for 15 min at 4 °C. This mixture
was three times filtered and then the supernatant was
evaporated by employing rotary under reduced pressure
at 40 °C. Such prepared turmeric extract was used at
two different concentrations: 100 mg/0.2 mL, 200 mg/
0.2 mL [28]. The voucher specimen (no. 12215) was
deposited at the herbarium of Ardabil University of
Medical Science.
Serum biochemical factors evaluation
Blood samples collected from the retro-orbital plexus
were centrifuged at 2500 rpm for 15 min at 30 °C for
sera preparation. The sera were then stored at −30 °C
and later the following parameters were measured: ala-
nine aminotransferase (ALT), aspartate aminotransferase
(AST), alkaline phosphatase (ALP), Albumin (ALB), and
total protein (TP). ALT and AST are markers for hepato-
cyte injury, ALP and bilirubin are sensitive markers to
investigate about biliary function, while albumin reflects
liver synthetic function [29]. Measurements were done
according to the corresponding kits instructions using a
colorimetric autoanalyzer [30].
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Measurement of antioxidants
Measurement of total antioxidant status (TAS)
Blood samples were centrifuged at 4000 rpm for 10 min.
Plasma TAS was measured using an automated colori-
metric of the total antioxidant response (TAR) which
was described previously [31]. In this method, Fe2+–o-
dianisidine reacts with hydrogen peroxide by the Fenton
reaction to produce OH•. The hydroxyl radical then re-
acts with o-dianisidine to produce yellow-brown colored
dianisyl product. The color formation is increased with
further oxidation reactions. By adding the samples, color
formation is decreased by the antioxidant components
of the plasma.
Measurements of liver superoxide dismutase (SOD)
The dissected tissues were immediately frozen in liquid
nitrogen and stored at −70 °C. Later the tissues were
homogenized in 1.15 % KCl solution and 20 % (W/V)
homogenate, which was later, centrifuged and then
used to measure SOD activity using spectrophotometric
method. The method was based on the inhibition of a
superoxide-induced nicotinamide adenine dinucleotide
(NADH) oxidation by a chemical reaction in the pres-
ence of EDTA, manganese (II) chloride and mercap-
toethanol as previously described [32].
Liver glutathione peroxidase (GSH-Px) activity
GSH-Px activity was determined in liver tissues [33].
Briefly this measurement is based on the conversion be-
tween the oxidized glutathione (NADPH) to the reduced
form (NADP). The rate of absorbance during this conver-
sion was measured using spectrophotometer at 340 nm
for 3 min. The activity of GSH peroxidase was expressed
as nmol of NADPH oxidized per min per mg DNA.
Liver catalase (CAT) activities
The method was previously described by Claiborne
group [34]. Briefly 50 μL of liver tissue lysate was added
to of H2O2 (10 mM, 0.95 mL) and later to reaction buf-
fer (60 mM phosphate buffer; pH 7.0). Catalase activity
was measured as micromoles of H2O2 consumed per mi-
nute at 25 °C. The changes in absorbance were recorded
at 240 nm using spectrophotometer.
Liver lipid peroxidation assay
Oxidative stress was evaluated using Malondialdehyde
(MDA) equivalents which were assessed utilizing the
thiobarbituric acid (TBARS) as reactive substrate [35].
The colorimetric reaction between MDA and TBARS)
were assayed (pH 2–3, 90 °C) for 15 min. The maximum
absorption was recorded at 532 nm.
Histopathological analysis
Liver tissue samples were taken from each animal, fixed
in 10 % neutral formalin and after histological process
of dehydration, tissue embedded in paraffin, section
with a microtome set at a thickness of 5–6 μm. The tis-
sue sections were stained with hematoxylin and eosin
(H&E) for histopathological analysis and examined with
a light microscope. The degree of liver tissue injury was
evaluated semiquantitatively according to the method
reported by Jamshidzadeh et al. [36]. The stained 5 μm
sections were graded as follows: 0, absent; 1, minimal;
2, mild; 3, modest; 4, severe. The histological changes
were evaluated in nonconsecutive, randomly chosen ×
200 histological fields using light microscope, NIKON
ECLIPSE E200. Neutrophils were counted in 50 high-
power fields (×400). The pathologist performing the histo-
logic evaluation had no knowledge about the treatment of
the animals, from which the samples originated.
Data analysis
The Statistical Package for Social Sciences (SPSS Inc.,
Chicago, IL, USA), version 17.0, was used for statistical
analysis. All data are presented as mean ± SD. Before stat-
istical analysis, all variables were checked for normality
and homogeneity of variance by using the Kolmogorov-
Smirnoff and Levene tests, respectively. The data obtained
were tested by ANOVA followed by Tukey’s posthoc mul-
tiple comparison test. The Kruskal-Wallis test, followed
by Mann–Whitney U posttest, was used for the analysis of
degree of histopathological liver injury. P < 0.05 was con-
sidered statistically significant.
Results
Effect of turmeric on antioxidant status in rat liver
The liver antioxidant markers (SOD, GSH-Px and CAT)
are shown in Table 2 for different groups. MTX signifi-
cantly (P < 0.05) decreased SOD, GSH-Px and CAT ac-
tivities in liver tissue compared to control, turmeric
(100 mg/kg) and turmeric (200 mg/kg) groups. However,
the groups, which were treated with MTX in presence of
TUR, (200 mg/kg) showed significant increase in SOD,
GSH-Px and CAT activity in liver tissue compared to
Table 1 Schematic diagram of the study protocol
Groups Number
of rats
Treated
protocol
Drugs
received
MTX dose TUR dose
(For 30 days) (On 30th
day)
(mg/kg/
day)
(mg/kg/
day)
I 7 Saline NaCl - -
II 7 TUR NaCl - 100
III 7 TUR NaCl - 200
IV 7 Saline MTX 20 -
V 7 TUR MTX 20 100
VI 7 TUR MTX 20 200
TUR Turmeric, MTX Methotrexate
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MTX group (P < 0.05). On the other hand turmeric
(100 mg/kg) and turmeric (200 mg/kg) control groups did
not show any significant changes in the activities of SOD
and GSH-Px, while CAT level were significantly increased
compared to control group in the liver tissue (P < 0.05).
Effect of turmeric on lipid proxidation and total
antioxidant status in liver and plasma
The hallmarks of lipid peroxidation and total antioxidant
(MDA and TAS) are shown in Table 3. Liver’s MDA con-
tent was significantly increased in MTX group compared
to control group (P < 0.05). Whereas, the concentration of
MDA in liver tissue was significantly decreased in group
VI treated with turmeric 200 and MTX when compared
to MTX group (P < 0.05). TAS was significantly decreased
in MTX group while turmeric 200 mg/kg induce an
increase in plasma TAS compared to control group
(P < 0.05). In the group which TUR 200 and MTX was
used, plasma TAS was significantly elevated compared to
MTX group (P < 0.05).
Effect of turmeric on the serum ALT, AST, ALP, Bilirubin,
ALB and TP
The results of serum liver biochemical hallmarks are pre-
sented in Table 4. MTX treatment significantly increased
serum ALT, AST, ALP activity and bilirubin concentration
(P < 0.05) while induced a significant decrease in serum
ALB and TP (P < 0.05) compared to control group. Also,
the same trends were observed in comparison between
the group, which was treated with turmeric 100 +MTX
and the control group. The group, which was treated with
turmeric +MTX, significant had lower ALT, AST, ALP
serum activity, and bilirubin concentration compared to
the MTX group (P < 0.05). Likewise, significant increases
were observed in ALB and TP concentrations in turmeric
200 +MTX group, compared to MTX group (P < 0.05).
Effect of turmeric on liver to body weight ratio
The liver/body weight ratios in different groups are
shown in Fig. 1. The body weight loss was observed for
rats receiving MTX (P < 0.01) and MTX + turmeric
100 mg/kg (group V) (P < 0.05) compared to control
(Fig. 1a). The body weight loss in-group treated with
MTX + turmeric 200 mg/kg was also observed, as com-
pared with the control group. However, the body weight
loss was not significant (P > 0.05) in this group. The liver
weights of groups IV,V,VI were significantly higher than
the control group, suggesting hypertrophy of the liver
(Fig. 1b). This is further emphasized by the fact that liver
weight/body weight ratio of group IV was significantly
(P < 0.01) higher than the groups I, II, and III (Fig. 1c).
In addition, a significant decrease in liver to body weight
ratio was observed in animals treated with MTX + tur-
meric 200 mg/kg compared to group receiving MTX
(P < 0.05). The liver/body weight ratio was higher in the
group given MTX + turmeric 100 mg/kg in comparison
with the control group (P < 0.05) (Fig. 1c).
Histopathology study
Histopathology examination of liver sections of the
normal group were stained with H&E, showed in low
magnification with normal appearance of central vein
(cv, indicated by arrow) and portal triad structures
(arrowhead) (Fig. 2ab). The cord-like structure of dis-
tinct polyhedral-shaped large hepatocytes well-preserved
cytoplasm and rounded euchromatic nucleus with prom-
inent nuclei showed around the central vein (pericentral
zone) (Fig. 2c). The normal appearance of portal vein
(v), artery (a), and bile duct (d) showed in portal triad
that embedded in hepatocytes cords in periportal zone
(Fig. 2d).
In turmeric (100 mg/kg) treatment group, no obvious
histopathological changes were observed in the liver sec-
tion of this group in pericentral zone (Fig. 3a) and peripor-
tal zone (Fig. 3b). In examination of hepatic tissue from
turmeric (200 mg/kg) treatment group, liver tissue had
normal appearance and there were no histopathological
changes as shown in pericentral zone (Fig. 3c) and peri-
portal zone (Fig. 3d).
Table 2 Effect of turmeric on antioxidant status in rat liver
Groups SOD (U/mg protein) GSH-Px (U/mg protein) CAT (U/mg protein)
Control 3.34 ± 0.32 3.9 ± 0.39 2.21 ± 0.24
TUR (100mgkg−1) 3.77 ± 0.39 4.22 ± 0.72 2.54 ± 0.51
TUR (200mgkg−1) 4.43 ± 0.53 4.67 ± 0.58 3.33 ± 0.65a
MTX (20mgkg−1) 1.76 ± 0.25a 2.12 ± 0.23a 1.03 ± 0.27a
TUR (100mgkg−1) + MTX 2.13 ± 0.41a 2.84 ± 0.26a 1.36 ± 0.14a
TUR (200mgkg−1) + MTX 3.08 ± 0.36b 3.23 ± 0.31b 2.11 ± 0.19b
Values of SOD, GSH-Px and CAT are shown as mean ± S.D.
TUR Turmeric, MTX Methotrexate, SOD superoxide dismutase, GSH-Px Glutathione peroxidase, CAT Catalase. aSignificant different with control group at P < 0.05.
bSignificant different with MTX at P < 0.05
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Examination of liver tissues from MTX treatment
group showed severe histopathological changes that
prominent around dilation and congestion of central
vein (cv) and portal vein (v) (Fig. 4). In pericentral zone
of liver tissues from MTX treatment group showed in-
flammation and degenerating hepatocytes with condense
nuclei (Fig. 4ab). The severe histopathological changes
were prominent in periportal zone with appearance of
hyperemia of portal vein, and inflammatory cells infiltra-
tion (Fig. 4cd). The necrotic cells and degenerating he-
patocytes with condense nuclei and lack of polygonal-
shaped outline were obvious in periportal zone that
indicate severe toxicity effects of MTX to liver and
hepatocyte (Fig. 4d).
To determine whether pretreatment of turmeric re-
duces the toxicity of MTX, we have treated animals with
turmeric (100 and 200 mg/kg) and followed by adminis-
tration of MTX. The histopathological studies of liver
section from showed an improvement in damages
caused by MTX to the hepatic tissues in a dose
dependent manner (Fig. 5). Microscopic image from
liver tissues of animals which have been treated with
MTX in the presence of turmeric (100 mg/kg) (group
IV) showed moderate pericentral zone hepatocytes de-
generation with clear nuclei and nucleoli (Fig. 5a). A
section from portal triad area showed that periportal
zone has a moderate degeneration while mild hyperemia
was still retained in portal vein (Fig. 5b). MTX treatment
in presence of turmeric (200 mg/kg) treatment (group
VI), showed degeneration significantly decreased in peri-
central zone (Fig. 5c) and Periportal zone (Fig. 5d).
Histopathological examination of livers form group VI
shows that most of hepatocytes appeared with concen-
tric arrangement and prominent nuclei and nucleoli.
Quantitative assessment of the samples shown in Fig. 6
(microscopic evaluation) are presented in Table 5.
We have next assessed the liver infiltration by neutro-
phils. In control livers, relatively few neutrophils were
observed in sinusoids (7 ± 2 PMN/50 HPF). The tur-
meric treatment alone (100 and 200 mg/kg) had no sig-
nificant effect on PMN level in the treated groups (7 ± 1
& 6 ± 1 PMN/50 HPF). The number of neutrophils
increased significantly (P < 0.05) in MTX treated groups
(237 ± 8 PMN/50 HPF). In general, turmeric at 100 mg/
kg, had no significant effect on hepatic neutrophile
counts (210 ± 5 PMN/50 HPF) regardless of the group.
In contrast, turmeric at the dose of 200 mg/kg (21 ± 3
PMN/50 HPF) had significant effect (P < 0.05) when
compared between MTX treated groups (Fig. 6).
Discussion
Several histopathology and serology markers have been
previously used to investigate MTX-induced liver tox-
icity, including increased relative fatty acid changes in
hepatocytes and sinusoidal lining cells, necrosis, inflam-
mation and elevated activities of serum ALT and AST
[13, 37, 38]. In the current study, histology outcomes
confirm MTX-induced hepatotoxicity, and biochemical
results are in agreement with the histological findings. As
MTX mechanism of action is involved in folate antagon-
ism, some of its toxicity effects such as anemia, neutro-
penia and stomatitis could be prevented or alleviated
by folate supplementation. But there are other effects,
which are unrelated to suppression of folate metabolism,
including hepatic fibrosis, pulmonary fibrosis, nodulosis,
Table 3 Effect of turmeric on lipid proxidation and total
antioxidant status in liver and plasma
Groups MDA
(nmol/mg protein)
TAS
(mmol Trolox Eq/L)
Control 2.34 ± 0.49 1.5 ± 0.43
TUR (100mgkg−1) 2.12 ± 0.52 1.78 ± 0.26
TUR (200mgkg−1) 1.9 ± 0.33 2.39 ± 0.41a
MTX (20mgkg−1) 4.27 ± 0.73a 0.78 ± 0.06a
TUR (100mgkg−1) + MTX 3.76 ± 0.61 1.08 ± 0.16
TUR (200mgkg−1) + MTX 3 ± 0.59b 1.42 ± 0.23b
Values of MDA and TAS are shown as mean ± S.D.
TUR Turmeric, MTX Methotrexate, MDA Malondialdehyde, TAS Total Antioxidant
Status. a Significant different with control group at P < 0.05. b Significant
different with MTX at P < 0.05
Table 4 Effect of turmeric on the serum levels of ALT, AST, ALP, Bilirubin, ALB and TP
Groups ALT AST ALP Bilirubin ALB TP
(U/L) (U/L) (IU/L) (mg/dl) (g/dl) (g/dl)
Control 36.53 ± 2.1 51 ± 2.57 186.59 ± 8.68 0.81 ± 0.04 3.67 ± 0.28 6.65 ± 0.55
TUR (100mgkg−1) 34.43 ± 0.18 50.59 ± 2.3 188.43 ± 8.54 0.83 ± 0.06 3.44 ± 0.42 6.82 ± 0.59
TUR (200mgkg−1) 33.9 ± 0.45 49.26 ± 0.36 184.99 ± 8.62 0.85 ± 0.05 3.42 ± 0.54 7.05 ± 0.69
MTX (20mgkg−1) 49.91 ± 2.11a 74.83 ± 3.89a 276.61 ± 10.56a 1.46 ± 0.1a 2.36 ± 0.37a 4.28 ± 0.41a
TUR (100mgkg−1) + MTX 42.42 ± 1.32a 63.48 ± 0.25a 226.78 ± 9.25a 1.21 ± 0.08a 2.9 ± 0.2a 5.48 ± 0.46a
TUR (200mgkg−1) + MTX 39.07 ± 0.4b 57.83 ± 0.31b 209.42 ± 8.7b 0.88 ± 0.07b 3.48 ± 0.38b 6.15 ± 0.57b
Values are shown as mean ± S.D.
TUR Turmeric, MTX Methotrexate, ALT Alanine Aminotransferase, AST Aspartate aminotransferase, ALP Alkaline phosphatase, ALB Albumin, TP Total protein.
aSignificant different with control group at P < 0.05. bSignificant different with MTX at P < 0.05
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Fig. 1 Effect of turmeric and methotrexate on body weight, liver weight, and liver weight/body weight ratio. a The body weight, (b) liver weight,
and (c) body weight/liver weight ratio are shown. Values of body weight and liver weight are shown as mean ± S.D.* P < 0.01 compared with
control, ** P < 0.05 compared with control, *** P < 0.05 compared with MTX group
Fig. 2 Histopathology examination of liver sections of the control group. a, b Microscopic view from the liver tissue of a rat belonged to healthy/
control group stained with H&E (group I). c Microscopic view from the pericentral zone of rat liver stained with H&E (group I). d Microscopic view
from the periportal zone of rat liver stained with H&E. Portal triad structures comprise of portal vein (v), hepatic artery (a), and bile duct (d) (group
I). (central vein = cv), Scale bars = 200 μm in A; 100 μm in B; 20 μm in C and D
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Fig. 3 Histopathology examination of liver sections of the group treated with tumeric. a Microscopic view from the pericentral zone of a rat liver
belonged to turmeric (100 mg/kg) treatment group stained with H&E (groups II and III). b Microscopic view from the periportal zone of a rat liver
belonged to turmeric (100 mg/kg) treatment group stained with H&E. c Microscopic view from the pericentral zone of a rat liver belonged to
turmeric (200 mg/kg) treatment group stained with H&E (groups II and III). d Microscopic view from the periportal zone of a rat liver belonged to
turmeric (200 mg/kg) treatment group stained with H&E (groups II and III). Portal triad structures comprise of portal vein (v), hepatic artery (a), and
bile duct (d) (central vein = cv, Scale bars = 20 μm in A, B, C and D)
Fig. 4 Histopathology examination of liver sections of the group treated with MTX. a, b Microscopic view from the pericental zone rat liver
belonged to MTX-group stained with H&E (group IV). c, d Microscopic view from the periportal zone of rat liver belonged to MTX-group stained
with H&E. Portal triad structures comprise of portal vein (v), hepatic artery (a), and bile duct (d) (group IV) (central vein = cv). Scale bars = 20 μm in
A and D; 100 μm in B
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lethargy and renal insufficiency [39–41]. Several studies
have shown that MTX-induced hepatic fibrosis is medi-
ated through oxidation and adenosine pathways (Fig. 7).
Adenosine is a potent endogenous regulator of inflamma-
tion and tissue repair. Adenosine, which might be released
from injured and hypoxic tissue in response to toxins and
medications, may induce hepatic fibrosis in mice, presum-
ably via adenosine receptor [42–44].
Our results showed prominent pathological changes in
the liver tissue of MTX-treated animals including
inflammatory cells infiltration, severe centrilobular/inter-
mediate zone/ periportal degeneration, bile duct hyper-
plasia, hyperemia and necrosis observed compared to
control and turmeric groups. Interestingly turmeric
ameliorated the histological alteration in hepatocytes
induced by MTX including decrease in periportal de-
generation, hyperemia, necrosis, and prevention of in-
flammatory cells infiltration. The histology results were
later confirmed by biochemical findings as have been
mentioned in the previous sections.
Curcumin is the prevalent ingredient of turmeric and
has been shown to possess several pleiotropic beneficial
effects in many iatrogenic organ maladies [45, 46].
Animal studies have shown that curcumin might have
positive effect against a wide range of human diseases,
Fig. 5 Histopathology examination of liver sections of the group treated with tumeric and MTX. a Microscopic view from the pericentral zone of
a rat liver belonged to turmeric (100 mg/kg) + MTX treatment group stained with H&E (groups V and VI). b Microscopic view from the periportal
zone of a rat liver belonged to turmeric (100 mg/kg) + MTX treatment group stained witch H&E (groups V and VI). c Microscopic view from the
pericentral zone of a rat liver belonged to turmeric (200 mg/kg) + MTX treatment group stained with H&E (groups V and VI). d Microscopic view
from the periportal zone of a rat liver belonged to turmeric (200 mg/kg) + MTX treatment group stained with H&E (groups V and VI). Portal triad
structures comprise of portal vein (v), hepatic artery (a), and bile duct (d) (central vein = cv). Scale bars = 20 μm in A, B, C and D
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Fig. 6 Effect of turmeric on PMN content of MTX-induced hepatic
injuries. The number of neutrophils was obtained by counting these
cells in 50 high-power fields. In control livers, relatively few neutrophils
were found at sites of erosion. Similar results were obtained in group II
and III. There was a significant increase in the number of neutrophils in
the liver of rats treated with MTX (P < 0.05). There was no statistically
significant difference between number of neutrophils in rats treated
with MTX + turmeric (100 mg/kg) as compared to livers obtained from
rats injected with MTX (group IV). However, the number of neutrophils
accumulating in the liver in group (MTX + turmeric 200 mg/kg) has
been significantly different compared to MTX treatment group
(P < 0.05). Values are shown as mean ± S.D. * P < 0.05 compared with
control, ** P < 0.05 compared with MTX group
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including diabetes, obesity, neurologic and psychiatric
disorders, and cancer, as well as chronic illnesses
affecting the eyes, lungs, liver, kidneys, and gastrointes-
tinal and cardiovascular systems [47–49]. Curcumin has
anti-inflammatory, anti-oxidant, pro-apoptotic, chemo-
preventive, chemotherapeutic, anti-proliferative, wound
healing, anti-nociceptive, anti-parasitic, and anti-malarial
effects as well [50–52]. However, besides curcumin,
Tumeric extracts cointain many other active constituents
such as turmerin, demethoxycurcumin, bisdemethoxycur-
cumin (two main active components of curcuminoids),
turmeric proteins content, fats, minerals, carbohydrates,
and essential oils, which could affect different biological
functions and target specific organs, which depends on
their molecular targets [53, 54]. Studies, over the two past
decades, on turmeric extracts have indicated that its ac-
tivities favorably compare to pure curcumin [27]. For ex-
ample, curcumin is less potent than turmeric in delaying
STZ-induced cataract [53] and in reducing blood glucose
levels in type 2 diabetic [55].
Oxidative stress-induced cell damage is a major factor
in the pathogenesis of many acute and chronic diseases
[56–59]. The cell damage is initiated by the reaction of
free radicals with membrane lipids and polyunsaturated
fatty acids [60]. The current study showed that a single
dose of MTX (20 mg/kg) caused significant hepatotoxicity.
The level of MDA in liver tissue was significantly in-
creased in MTX-treated rats compared to control group,
Table 5 Effect of turmeric on hepatic injuries
Groups Degree of liver tissue
injury
The Kruskal-Wallis
tes
Control 0.0 ± 0.0 P < 0.001
TUR (100mgkg−1) 0.0 ± 0.0
TUR (200mgkg−1) 0.0 ± 0.0
MTX (20mgkg−1) 2.83 ± 0.78a
TUR (100mgkg−1) +
MTX
2.20 ± 0.61a
TUR (200mgkg−1) +
MTX
0.45 ± 0.18b
Values are shown as mean ± S.D.
TUR Turmeric, MTX Methotrexate
0 = without injury, 1 =minimum injury, 2 = mild injury, 3 = moderate injury,
4 = sever injury. aSignificant different with control group at P < 0.05.
bSignificant different with MTX at P < 0.05
Curcumin 
Bisdemethoxycurcumin 
Demethoxycurcumin 
Methotrexate 
Mitochondrial 
damage 
Tissue injury 
Adenosine 
pathway 
Damaged hepatic cell 
Normalized hepatic cell 
- Inflammation 
- Necrosis 
- Bile duct hyperplasia 
- Portal vein hyperemia 
- Central vein congestion 
- Kupffer's cells  
- Proliferation 
- Congestion of portal vein 
LPO 
MDA 
TAS  
SOD 
CAT 
     GSH-Px 
ALT 
AST 
ALP 
ALB 
         TP 
      Bilirubin 
Biochemical hallmarks & 
antioxidant capacity 
ROS 
Turmeric 
(Structures of most 
relevant components) 
- Hepatocyte injury 
- Biliary function 
- Liver synthetic function        
- Antioxidant defenses 
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Antioxidant capacity 
Fig. 7 Schematic representation of the beneficial effects of turmeric on MTX induced liver toxicity. Turmeric plays an important role in
modification of liver injury caused by MTX. The turmeric mostly exerts its effects by regulation of antioxidant capacity including enzymatic (SOD
and CAT) and non-enzymatic antioxidants (GSH) as well as lipid peroxidation. It also modulates some liver related biochemical parameters causing
in improvement of biliary and hepatic synthetic functions. Interestingly turmeric can normalize the histological changes in hepatocytes induced
by MTX such as decrease in periportal degeneration, hyperemia, necrosis, and prevention of inflammatory cells infiltration
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which suggested that the peroxidation reaction was higher
than control group in MTX-treated animals and corre-
lated with the previous research findings about MTX-
induced hepatoxocity [7, 11, 61, 62]. Our findings suggest
that turmeric ROS scavenging-induced protective response
markedly decreased MDA concentration. Comparable
antioxidant effects were reported by other researchers in
pulmonary, neurological, metabolic, and cardiovascular
diseases [27]. Turmeric pre-treatment (200 mg/kg) showed
higher improvement and recovery of liver tissue in pres-
ence of lipid peroxidation inhibition (e.g. 30 %) compared
to group treated with turmeric (100 mg/kg). Hemeida and
colleagues have previously shown that curcumin post-
injection could decrease MTX-induced MDA production
by around 24 % [13].
Our study also indicate that MTX-induced liver injury
activates neutrophiles and results in liver infiltration by
PMN. Neutrophil accumulation in the liver occurred
parallel to the development of hemorrhage and paren-
chymal cell injury. Infiltration of neutrophils of liver
tissues was concomitant with the oxidant/antioxidant
status and changes in MDA levels. Increased MDA levels
in the rat-livers after MTX administration suggests acti-
vation of an inflammatory response. We observed in-
creased MDA levels in the liver tissue, and this may
indicate that neutrophil accumulation and lipid peroxi-
dation contributes to MTX-induced liver injury. Likely,
the activated neutrophils located in the area of inflam-
mation, may convert hydroperoxides into free radicals,
triggering lipid peroxidation and hepatocyte cell mem-
brane damage.
In our study, SOD and CAT activities were also signifi-
cantly decreased in MTX treated group compared to
healthy control group. SOD and CAT are the main en-
zymes, which are involved in H2O2 and ROS scavenging
[63]. SOD and CAT activities were increased in all
groups treated with turmeric-MTX compared to groups,
which received MTX alone. SOD activity was increased
27 % and 75 % in the groups, which were pre-treated
with tumeric (100 mg/kg and 200 mg/kg) before MTX
exposure respectively, while CAT activity were increased
32 % and 105 % respectively. Similar results, in different
tissues, were reported by others [13, 64–66].
The present study also shows that MTX could reduce
GSH, which indicates imbalance between antioxidants
and oxidants in the liver. As GSH is one of the most im-
portant parts of antioxidant defense system [67], when
MTX decreases the level of GSH, cellular redox state
alters and cells could be more sensitive to reactive
oxygen metabolites [68]. Such findings have been ob-
served in other experimental systems [69]. One of the
possible mechanisms related to GSH depletion is based
on the decrease of NADPH availability due to MTX in-
hibitory effects on glucose 6 phosphate dehydrogenase
[70]. Glutamine is necessary for glutathione production.
A study indicated that intravenous glutamine supple-
mentation could protects liver cells from MTX-induced
oxidative damage due to increasing intercellular GSH
level [71] as turmeric increased GSH level with un-
known mechanism. Our results show that turmeric not
only affected enzymatic cellular antioxidant machinery
(SOD and CAT), but also non-enzymatic defense system
(GSH). Preadministration of turmeric (100 and 200 mg/
kg) in groups V and VI for 30 days can significantly re-
store the GSH level about 34 % and 54 % respectively
compared to groups that received MTX alone.
Total antioxidant status (TAS) reflects the total effect
of all antioxidants in plasma [72]. In our study, the level
of TAS in rats treated with MTX, were significantly
lower compared to healthy control group. Previous stud-
ies indicated decreased antioxidant capability and in-
creased oxidative stresses provokes hepatic damage [42,
56, 73]. In groups V and VI (turmeric +MTX), serum
TAS were elevated compared to group III (MTX treated
animals), but statistically significant results were ob-
tained when we used higher concentration of turmeric
(200 mg/kg). We have previously shown that dietary tur-
meric can markedly enhance TAS level under physilogi-
cal conditions in rats [74].
In our study, MTX increased serum activities of ALT,
AST, ALP and bilirubin serum concentration and de-
creased the concentrations of ALB and TP, which are
hepatotoxicity and impaired liver function indicators
[75, 76]. ALT and AST are the major critical enzymes in
the biological processes [77, 78]. Reports have suggested
that their levels increase in different hepatic injures such
as hepatitis and cirrhosis induced by alcohol, drugs,
viruses and also under oxidative stress [79]. Also there
are not similar studies about ALP, ALB, and TP levels in
MTX induced liver toxicity. Our investigation revealed
that in turmeric 200 +MTX group, serum activities of
ALT, AST, ALP and serum bilirubin concentration were
decreased, and levels of ALB and TP were increased
compared to MTX group which correlates to previous
reports [13, 80]. The low and high concentrations of tur-
meric did not induce any significant changes in ALT, AST
and ALP levels compared to control group which con-
firms the previous finding [81]. Recently Fu et al. demon-
strated that turmeric could effectively protect liver against
CCL4-induced injury. They also showed that it prevented
AST and ALT augmentation and improved the liver cell
function [76]. In a randomized clinical trial on patients
with increased levels of ALT, fermented turmeric powder
decreased serum ALT and AST while there were not any
significant changes in serum ALP, TB and lipids concen-
trations [82]. The results are varying among the investiga-
tors because of different methods of study or different
population, which has been studied.
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Conclusion
In conclusion turmeric could prevent MTX hepatotox-
icity and it might have a great potential for application
in future disease therapy strategies. Liver-, breast- and
other cancers often require aggressive chemotherapy,
preferably targeting cancer stem cells [83–89]. The fu-
ture clinical trials should be arranged to investigate the
actual effect of turmeric in human patients and the pos-
sibility of considering this medical herb as a potential
additive to MTX anticancer drugs.
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